Octane Publications

Rethinking clinical delivery of adult stem cell therapies

In this thoughtful commentary, Octane leaders and scientists Tim Smith, Alexis Pietak and Nuala Trainor discuss how major challenges in the Good Manufacturing Practice (GMP) production of clinically significant numbers of autologous adult stem cells can be addressed by automated cell culture “GMP-in-a-box” systems. Such an approach may result in a distributed, decentralized model where personalized cell therapies are produced at point-of-care in primary care facilities.

Nature Biotechnology, 32, 729–735 (2014)
Authors: Nuala Trainor, Alexis Pietak and Tim Smith


We’re advancing personalized cell therapy as the standard of care through a partnership between Octane Biotech and the Lonza Group

Recent Publications

Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products – Trends in Biotechnology

How can automated bioreactor technology accelerate the commercialization of cell and tissue therapy products for regenerative medicine? This scientific article ...

Crystallization kinetics of Si-TCP bioceramic films – Journal of Materials Science

Along with two other researchers, Octane scientist Alexis Pietak examines the crystallization kinetics in the transformation of an unfired hydroxyapatite ...

Structure and composition of silicon-stabilized tricalcium phosphate – Biomaterials

Silicon stabilized tricalcium phosphate [Si-TCP] is a bioceramic of major biological interest because of its osteoconductivity and unique influence on ...